Erasca Announces Proposed Public Offering of $500 Million of Common Stock
Erasca, Inc., a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced its intent to offer $500 million of common stock in a public offering, with an additional 30-day option for underwriters to purchase $75 million more. The proceeds will be used to advance research and development of its cancer therapies a…